Stock Price & Analysis

Based on the latest data and market conditions, ICLR stock appears to be in a challenging position. The stock is currently trading at $193.16, showing weakness with a -1.79% decline in regular market trading.

Technical Analysis

• Currently trading below both its 20-day SMA of $205.87
• RSI at 37.57 indicates approaching oversold territory but not extreme
• Fibonacci support levels suggest immediate support at $194.96, with stronger support at $191.73

Recent Developments

• Management recently issued FY25 guidance that fell below market expectations
• Two of its largest customers are reportedly undergoing substantial reconstructions
• The company's book-to-bill ratio dropped to 1.15x in Q3, below the long-term target range

Analyst Sentiment

• Recent analyst actions show mixed but generally positive views:
• JP Morgan maintained Buy rating with PT lowered to $265 (Feb 3, 2025)
• RBC Capital reiterated Buy with $263 PT (Jan 15, 2025)
• William Blair maintained Buy rating (Jan 14, 2025)

Conclusion Based on the technical weakness, recent guidance disappointment, and customer challenges, selling ICLR stock at current levels appears to be the prudent action. While long-term fundamentals remain intact, near-term headwinds suggest better entry points may emerge in the future.

Based on the provided data and recent market developments, here's the price prediction analysis for ICLR stock in 2025:

Technical Analysis The stock is currently trading at $195.51, showing a significant decline from its recent highs around $340 in early 2024. The stock has formed a strong support level around $190-195 range, with current price action suggesting potential consolidation.

Fundamental Drivers According to recent guidance, ICON plc announced its 2025 financial outlook:

• Revenue projection: $8.05-8.65 billion
• Adjusted EPS guidance: $13.00-15.00
• Growth rate: Approximately 1% at midpoint

Analyst Consensus Multiple analysts maintain positive ratings:

• Evercore ISI: Buy rating with $240 target
• Jefferies: Buy rating with $252 target
• Overall consensus: Strong Buy with average target of $267.93

Price Prediction for 2025 Based on technical patterns, fundamental outlook, and analyst consensus, ICLR stock is expected to reach $240-250 by end of 2025. This projection is supported by:

1. Strong analyst buy ratings despite near-term headwinds
2. Company's strategic initiatives including $400M stock buyback
3. Solid competitive positioning in clinical research sector

The S1 support level for ICLR Stock is $194.57 ,The R1 resistant level for ICLR Stock is $205.01.

As of the end of day on 2025-02-05, the price of ICLR Stock was $190.

The target price for ICLR Stock according to analyst rating is 261.77, with the highest price target at 290.00 and the lowest at 240.00. Analysts have a Strong Buy rating on ICLR Stock overall.

The market cap of ICLR is $16.0B.

Based on the provided data, I'll analyze whether ICLR is overvalued.

Valuation Metrics The current valuation metrics show ICLR trading at:

• P/E (Q3 2024): 31.93x
• EV/EBITDA (Q3 2024): 15.70x
• P/S (Q3 2024): 2.88x
• P/B (Q3 2024): 2.43x

Financial Performance

• Revenue shows steady performance with Q3 2024 at $2.03B
• Net income improved to $197.1M in Q3 2024 from $146.9M in Q2
• Gross margin expanded to 24.55% in Q3 from 22.49% in Q2
• ROE improved to 7.98% in Q3 from 7.77% in Q2

Recent Events Impact ICLR stock fell 9.22% after issuing FY25 guidance with midpoint below estimates. However, analysts maintain positive outlook with recent price targets:

• JP Morgan: $265 (Feb 2025)
• RBC Capital: $263 (Jan 2025)
• William Blair: Buy rating (Jan 2025)

Conclusion ICLR is moderately overvalued considering its current valuation multiples against historical trends and recent guidance disappointment. The declining trend in valuation metrics (P/E dropping from 40.76 in Q1 to 31.93 in Q3) suggests market adjustment to more realistic levels.

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Based on the available data and analyst projections, here's the 2030 price prediction for ICON plc (ICLR):

ICON's stock price is projected to reach $375-400 by 2030, driven by sustained growth in clinical research outsourcing and strategic market positioning. The company's strong competitive position in the CRO industry and expanding commercial customer base support this target.

Multiple analyst firms maintain Buy ratings with near-term price targets of $240-275, indicating confidence in ICON's growth trajectory despite current market challenges [2,3].

The clinical research market's projected CAGR of 20% through 2030 provides a solid foundation for ICON's long-term revenue expansion and stock appreciation potential.

ICLR has a total of 41100 employees.